Showing 15 posts of 50 posts found.

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

August 31, 2023
Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

June 7, 2023
Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …

Novo Nordisk to expand obesity study into oral treatment

April 22, 2021
Novo Nordisk, obesity

Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, expanding on its Phase IIIa …

Novo Nordisk obesity treatment successful in clinical trials

March 24, 2021
Research and Development Novo Nordisk, obesity

New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …


Obesity increases risk of death from coronavirus and could make vaccines less effective

August 27, 2020
Medical Communications obesity

Obesity can increase the risk of death from coronavirus by nearly 50% and could make a vaccine less effective, according …


Type 2 diabetes cases up 40% in Scotland

February 11, 2020
Manufacturing and Production Type 1 diabetes, diabetes, diabetes obesity, obesity, type 2 diabetes

According to a new study, Scotland’s cases of type 2 diabetes has increased by 40% over the last 10 years. …

NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use

January 27, 2020
Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda

NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …

Rhythm Pharma’s obesity drug shows positive results in two Phase 3 trials

August 8, 2019
Research and Development Rhythm pharma, clinical trial, health, obesity, pharma

Rhythm Pharma’s obesity drug setmelanotide achieved positive results in two pivotal Phase 3 trials. In both studies, setmelanotide met its …

Heart disease deaths increase for first time in 50 years

May 13, 2019
Sales and Marketing BHF, UK, cardiovascular, health, heart disease, obesity

Deaths from heart disease among people under the age of 75 have increased for the first time in 50 years. …


Obesity-related cancers on the rise amongst millennials

February 4, 2019
Sales and Marketing Cancer, obesity, oncology, young people

Cancers related to obesity are on the rise in young adults, according to findings from the American Cancer Society, published …


Effective preventative therapies for type 2 diabetes are underused, new research argues

October 30, 2018
Manufacturing and Production, Research and Development, Sales and Marketing diabetes, obesity, pharma, prediabetes, type 2 diabetes

New research has warned that interventions which can effectively delay or prevent the development of type 2 diabetes are not …

More children suffering from type 2 diabetes in England and Wales

August 20, 2018
Sales and Marketing England, NHS, Wales, children, diabetes, obesity, young people

The number of children and young people suffering from type-2 diabetes has increased in England in Wales over the past …


Kallyope and Novo Nordisk announce obesity and diabetes collaboration

June 20, 2018
Research and Development Kallyope, Novo Nordisk, diabetes, obesity, pharma

Kallyope and Novo Nordisk have entered into a research collaboration and option agreement to discover novel peptide therapeutics for the …


One in 25 English children are severely obese by secondary school, study finds

May 29, 2018
Manufacturing and Production, Research and Development England, UK, childhood obesity, obesity, pharma

A new analysis of Public Health England figures by the Local Government Association (LGA) has revealed that one in 25 …


Top Ten most popular articles on Pharmafile.com this week

May 25, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Gielad, Novartis, brexit, obesity, pharma, top ten

It’s a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an …

Latest content